Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro(Clinica Universidad de Navarra), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Ann‐Lii Cheng(National Taiwan University), Ignacio Melero(University of Oxford), Jaclyn Neely(Bristol-Myers Squibb (United States)), Marina Tschaika(Bristol-Myers Squibb (United States)), Junji Furuse(Kanagawa Prefectural Hospital Organization), Samir Wadhawan(Bristol-Myers Squibb (United States)), Richard S. Finn(University of California, Los Angeles), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Thomas Yau(University of Hong Kong), Hao Tang(Hainan University), Joong‐Won Park(National Cancer Center), Yun Shen(Bristol-Myers Squibb (United States)), Zachary Boyd(Genesys (United States))
Cited by 421
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k